U.S. Markets closed

GenMark Diagnostics Inc (GNMK) Files 10-K for the Fiscal Year Ended on December 31, 2018

- By insider

GenMark Diagnostics Inc (GNMK) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. GenMark Diagnostics Inc is a molecular diagnostics company. The Company develops and commercializes its proprietary eSensor detection technology for the support of instruments and molecular tests. GenMark Diagnostics Inc has a market cap of $429.670 million; its shares were traded at around $7.64 with and P/S ratio of 6.26.


For the last quarter GenMark Diagnostics Inc reported a revenue of $15.8 million, compared with the revenue of $11.60 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $70.8 million, an increase of 34.7% from last year. For the last five years GenMark Diagnostics Inc had an average revenue growth rate of 20.7% a year.

The reported loss per diluted share was 91 cents for the year, compared with the loss per share of $0.93 in the previous year. The GenMark Diagnostics Inc had an operating margin of -67.51%, compared with the operating margin of -113.32% a year before. The 10-year historical median operating margin of GenMark Diagnostics Inc is -127.47%. The profitability rank of the company is 4 (out of 10).

At the end of the fiscal year, GenMark Diagnostics Inc has the cash and cash equivalents of $36.3 million, compared with $26.8 million in the previous year. The long term debt was $36.0 million, compared with $20.1 million in the previous year. GenMark Diagnostics Inc has a financial strength rank of 4 (out of 10).

At the current stock price of $7.64, GenMark Diagnostics Inc is traded at 49.4% discount to its historical median P/S valuation band of $15.10. The P/S ratio of the stock is 6.26, while the historical median P/S ratio is 12.40. The stock gained 79.76% during the past 12 months.

CEO Recent Trades:

  • President and CEO Hany Massarany sold 5,562 shares of GNMK stock on 02/20/2019 at the average price of $6.16. The price of the stock has increased by 24.03% since.

CFO Recent Trades:

  • CFO John Frederick Ek sold 595 shares of GNMK stock on 02/20/2019 at the average price of $6.16. The price of the stock has increased by 24.03% since.

Directors and Officers Recent Trades:

  • COO Scott Mendel sold 2,063 shares of GNMK stock on 02/20/2019 at the average price of $6.16. The price of the stock has increased by 24.03% since.
  • SVP & General Counsel Eric Stier sold 1,986 shares of GNMK stock on 02/20/2019 at the average price of $6.16. The price of the stock has increased by 24.03% since.
  • SVP, Corp. Accounts Michael Gleeson sold 2,121 shares of GNMK stock on 02/20/2019 at the average price of $6.16. The price of the stock has increased by 24.03% since.
  • SVP, Operations Brian Andrew Mitchell sold 519 shares of GNMK stock on 02/19/2019 at the average price of $6.32. The price of the stock has increased by 20.89% since.

For the complete 20-year historical financial data of GNMK, click here.

This article first appeared on GuruFocus.